Prospera™ Transplant Assessment Test: Path Established to Expand Future Coverage to Multiple OrgansPRNewsWire • 04/22/21
Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGSPRNewsWire • 04/07/21
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic TestingPRNewsWire • 03/31/21
FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD TestPRNewsWire • 03/24/21
Natera and Genentech Initiate Phase III Trial Using Signatera™ as a Companion Diagnostic for Atezolizumab in Early-Stage Muscle-Invasive Bladder CancerPRNewsWire • 03/10/21
Natera, Inc. (NTRA) CEO Steve Chapman on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/28/21
Naturally Splendid appeals Federal Court of Canada's NATERA trademark decisionProactive Investors • 02/26/21
Natera (NTRA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/17/21
Panorama® SMART Study Confirms Market-Leading Performance in Largest Prospective NIPT Trial to DatePRNewsWire • 02/03/21
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ TestingPRNewsWire • 01/14/21
Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/05/21
U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA PatentPRNewsWire • 12/18/20
Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all PregnanciesPRNewsWire • 12/01/20
New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer PatientsPRNewsWire • 11/30/20